Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

NCT05967286 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Other - Protocol moved to Withdrawn

Conditions

Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Metastatic HER2-Negative Breast Carcinoma
Unresectable HER2-Negative Breast Carcinoma

Interventions

DRUG: Alpelisib
PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Scan
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
DRUG: Olaparib
PROCEDURE: Positron Emission Tomography

Sponsor

National Cancer Institute (NCI)